CF
SLN

Cantor Fitzgerald’s Silence Therapeutics SLN Stock Holding History

Cantor Fitzgerald’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-801,306
Closed -$4.16M – 352
2025
Q3 		$4.16M Buy
801,306
+12,267
+2% +$68.1K 0.04% 121
2025
Q2 		$4.58M Buy
789,039
+15,194
+2% +$65.1K 0.08% 60
2025
Q1 		$2.18M Buy
773,845
+234,119
+43% +$1.14M 0.05% 80
2024
Q4 		$3.71M Buy
539,726
+205,534
+62% +$2.65M 0.07% 45
2024
Q3 		$6.08M Buy
334,192
+86,226
+35% +$1.6M 0.17% 28
2024
Q2 		$4.71M Buy
247,966
+144,483
+140% +$3.07M 0.93% 26
2024
Q1 		$2.24M Sell
103,483
-43,294
-29% -$941K 0.53% 31
2023
Q4 		$2.55M Sell
146,777
-21,416
-13% -$240K 0.52% 34
2023
Q3 		$1.65M Sell
168,193
-125,700
-43% -$928K 0.04% 236
2023
Q2 		$1.62M Buy
293,893
+4,735
+2% +$28.6K 0.04% 272
2023
Q1 		$1.79M Sell
289,158
-12,532
-4% -$148K 0.04% 322
2022
Q4 		$4.6M Buy
301,690
+91,804
+44% +$1.2M 0.1% 251
2022
Q3 		$2.11M Sell
209,886
-1,574
-0.7% -$16.6K 0.05% 334
2022
Q2 		$2.51M Buy
211,460
+37,735
+22% +$458K 0.05% 335
2022
Q1 		$3.3M Sell
173,725
-80,794
-32% -$1.61M 0.25% 105
2021
Q4 		$6.08M Buy
+254,519
New +$5.89M 0.43% 52

Other funds holding SLN

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return

Cantor Fitzgerald's SLN Position: Q4 2025 in Review

Cantor Fitzgerald sold out of Silence Therapeutics (SLN) in Q4 2025, closing a stake of 801,306 shares — an estimated $4.16M sold.

Cantor Fitzgerald first reported a position in SLN in Q4 2021 and held it in 16 quarters. The position peaked at $6.08M in Q4 2021. 58 funds tracked by Wall St. Rank hold SLN as of Q4 2025.

  • Cantor Fitzgerald reported no remaining Silence Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Cantor Fitzgerald sold 801,306 Silence Therapeutics shares in Q4 2025, an estimated $4.16M.
  • Cantor Fitzgerald first reported a position in Silence Therapeutics in Q4 2021 and held it in 16 quarters.
  • Cantor Fitzgerald's Silence Therapeutics position peaked at $6.08M in Q4 2021.
  • 58 funds tracked by Wall St. Rank held Silence Therapeutics as of Q4 2025.

Based on Cantor Fitzgerald's 13F filing for Q4 2025, filed 17 Feb 2026.